Alternative TreatmentsThere are many alternative safe, effective, and convenient options for HAE prophylaxis approved and in development, such as Astria's navenibart.
Clinical Trial RisksThe general liver delivery and editing approach of Intellia's ATTR-CM and HAE programs are the same, adding additional risk/questions to NTLA-002 as more patients are enrolled.
Financial ConcernsThe company has an annualized cash burn of $126 million, with cash reserves expected to last approximately 2.3 years.